AbbVie Expands Oncology Capability at Ireland Site

January 24, 2018

The company will invest $139 million in sterile manufacturing technology at its facility in Ballytivnan, Sligo, Ireland to support the growth of its oncology pipeline.

AbbVie announced a $139-million investment to expand its manufacturing facility in Ballytivnan, Sligo, Ireland, to support the growth of its oncology pipeline. The expansion includes new sterile manufacturing technology, which will help deliver treatments for cancers with significant unmet medical needs, according to a Jan. 16, 2018 press release from Industrial Development Agency (IDA) Ireland, a non-commercial, semi-state body promoting foreign direct investment into Ireland.

The investment is expected to create approximately 100 new positions at the site over the next three years in technical and manufacturing positions, and is supported by the federal government through IDA Ireland, according to the agency.

“This investment demonstrates AbbVie’s commitment to Ireland, and the laser focus of our team in Sligo on making a remarkable impact on patients’ lives,” said Joe Kumor, director at the Sligo site, in an IDA Ireland press release. “We are proud to be recognized for our high performance over the years and are excited to have been chosen to help accelerate AbbVie’s oncology pipeline.”

Source: IDA Ireland